Psoriasis Clinical Trials in Lancaster
View 33 new treatments for Psoriasis in Lancaster, CA, and nearby areas, such as Palmdale. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Deucravacitinib for Scalp Psoriasis
Bristol-Myers Squibb Clinic, Los Angeles + 1 more
This trial is testing a medication called deucravacitinib to see if it can help people with moderate-to-severe scalp psoriasis. The medication works by blocking proteins that cause inflammation and immune responses, which are responsible for the red, itchy, and scaly patches on the scalp. The goal is to find out if this treatment is safe and effective.Show More
Waitlist
Phase 4
Est. 6 - 12 Weeks
Bristol-Myers Squibb
Study Chair
Subcutaneous Risankizumab for Psoriasis
AbbVie Clinic, Encino + 1 more
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Approximately 200 participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis will be enrolled across approximately 45 sites globally. The study will be broken up into 2 sub-studies by disease location, participants with moderate to severe genital psoriasis (Study G) and moderate to severe scalp psoriasis (Study S). In both sub-studies participants will receive subcutaneous (SC) injections of risankizumab during the 52 week treatment period, or SC injections of placebo risankizumab during the 16 week treatment period followed by SC injections of risankizumab during the 36 week treatment period, with an 8-week follow-up period after the 52 week treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting
Phase 4
Est. 4 - 6 Weeks
ABBVIE INC.
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Covina + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Los Angeles + 1 more
The purpose of this study is to measure the safety and effectiveness of deucravatinib in participants with non-pustular palmoplantar psoriasis and genital psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Tildrakizumab for Psoriatic Arthritis
Sun Clinic, Covina + 2 more
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Unregistered Study Lead
Research Team
Upadacitinib for Psoriatic Arthritis
AbbVie Clinic, Covina + 3 more
The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Upland + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 6 - 12 Weeks
AbbVie Inc.
Study Director
Tildrakizumab SC Injection for Psoriatic Arthritis
Sun Clinic, Covina + 1 more
An open label phase 3 study
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Upland + 1 more
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Encino + 1 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions